EUVIMEDEUVIMED entdecken
Crossref

Plasma Biomarker Screening Based on Proteomic Signature of Patients with Resistant Hypertension

Jianmin Du, Xiaoqian Yu, Wenyu Zhang, Xinghai Zhang, Hengli Zhao, Rui Xu, Qing Wen iD

Journal of Cardiovascular Translational Research · 2024

DOI: 10.1007/s12265-024-10541-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Translational Research, 2024. Verfasst von Jianmin Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China. Hauptthemen laut MEDLINE: Proteomics, Hypertension, Biomarkers, Protein Interaction Maps. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Jinan Technology Development Program, China, Shandong Province Medical and Health Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistant hypertension (RH) poses a significant health challenge, yet its underlying pathogenesis remains unclear. This study employs untargeted proteomic techniques to analyze the plasma of patients with RH and controlled hypertension (CH), identifying 157 differentially expressed proteins, with TGFB1 emerging as a key candidate. Through gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, Protein-Protein Interaction Networks (PPI) topological analysis, TGFB1's differential regulation in RH is established. ELISA verification solidifies TGFB1's role, marking it as a potential biological target for early RH diagnosis and treatment. The study underscores the importance of proteomic approaches in enhancing our understanding of RH and improving therapeutic strategies. These findings carry implications for advancing RH diagnostics and treatment modalities, addressing a critical gap in current knowledge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsHypertensionBiomarkersProtein Interaction MapsPredictive Value of TestsDrug ResistanceTransforming Growth Factor beta1HumansFemaleMaleMiddle AgedCase-Control StudiesAntihypertensive AgentsBlood PressureAgedEnzyme-Linked Immunosorbent AssayBlood Proteins

Stichwörter der Autor:innen

BiomarkerControlled hypertensionResistant hypertensionTGFB1Untargeted proteomics

Substanzen

BiomarkersTransforming Growth Factor beta1TGFB1 protein, humanAntihypertensive AgentsBlood Proteins

Autor:innen und Institutionen

  • Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
  • Department of Cardiology, Jinan Central Hospital, Shandong University, Jinan, 250013, China.
  • Department of Cardiology, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China. xuruicn@hotmail.com.
  • Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China. jnlcsy_stu@163.com.

ORCID-Profile: Qing Wen

Förderung

  • Jinan Technology Development Program, China
  • Shandong Province Medical and Health Technology Project

Zitieren

APA

Du, J., Yu, X., Zhang, W., Zhang, X., Zhao, H., Xu, R., & Wen, Q. (2024). Plasma Biomarker Screening Based on Proteomic Signature of Patients with Resistant Hypertension. Journal of Cardiovascular Translational Research. https://doi.org/10.1007/s12265-024-10541-7

Vancouver

Du J, Yu X, Zhang W, Zhang X, Zhao H, Xu R, et al. Plasma Biomarker Screening Based on Proteomic Signature of Patients with Resistant Hypertension. Journal of Cardiovascular Translational Research. 2024. doi:10.1007/s12265-024-10541-7

BibTeX
@article{Du2024,
  author = {Du, Jianmin and Yu, Xiaoqian and Zhang, Wenyu and Zhang, Xinghai and Zhao, Hengli and Xu, Rui and Wen, Qing},
  title = {Plasma Biomarker Screening Based on Proteomic Signature of Patients with Resistant Hypertension},
  journal = {Journal of Cardiovascular Translational Research},
  year = {2024},
  doi = {10.1007/s12265-024-10541-7}
}
Kostenlos starten →